Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

Zealand Pharma and Roche Advance Petrelintide to Phase 3 for Weight Management

Zealand Pharma and Roche announced their decision to advance petrelintide, a once-weekly amylin analog, into Phase 3 trials for chronic weight management. This move, planned for the second half of 2026, follows promising results from the ZUPREME-1 Phase 2 trial, which demonstrated double-digit weight loss with placebo-like tolerability. The collaboration aims to provide a highly tolerable and effective option for individuals living with overweight and obesity, addressing significant unmet needs in long-term weight management.

• The upcoming Phase 3 program for petrelintide will evaluate its efficacy, safety, and tolerability as a once-weekly subcutaneous treatment. It is specifically designed for adults living with obesity or overweight who have weight-related comorbidities, aiming to offer a highly tolerable alternative that promotes long-term adherence for sustained health outcomes.
• Petrelintide is a long-acting amylin analog administered once-weekly, engineered for chemical and physical stability. It functions by activating amylin receptors, which restores sensitivity to the satiety hormone leptin and induces a feeling of fullness faster, thereby reducing body weight. This mechanism positions petrelintide to address unmet needs by providing effective weight loss with exceptional tolerability.
• Zealand Pharma and Roche established an exclusive collaboration and licensing agreement in 2025 for petrelintide's co-development and co-commercialization. Beyond monotherapy, a Phase 2 trial is slated for the second quarter of 2026 to evaluate petrelintide in combination with Roche’s GLP-1/GIP receptor dual agonist, enicepatide (CT-388), exploring its full therapeutic potential.

Designing Petrelintide's Phase 3: Key Endpoints for Chronic Weight Management

Clinical trials in chronic weight management utilize standardized endpoints to evaluate therapeutic efficacy and safety. These endpoints provide regulatory bodies and clinicians with quantifiable measures to assess treatment benefits and guide clinical decision-making.

• Primary efficacy endpoints include mean weight loss, percentage weight loss from baseline, proportion of patients achieving ≥5% initial bodyweight loss, and proportion achieving ≥10% initial bodyweight loss

• Secondary endpoints encompass reduction in body fat mass, improvements in cardiovascular risk factors, and incidence of obesity-related comorbidities such as diabetes mellitus

• Metabolic parameters routinely assessed include waist circumference reduction, insulin sensitivity improvements, lipid profile changes, and cardiovascular health biomarkers

• Regulatory benchmarks typically require demonstration of ≥5% bodyweight loss at 12 weeks, with failure to achieve this threshold serving as an indication for treatment discontinuation

• Long-term efficacy measures have been validated in landmark studies, with sibutramine demonstrating ≥10% weight loss in 46% of patients at 2 years and orlistat showing 2.2 kg greater weight loss versus placebo at 4 years

• Patient-reported outcomes are increasingly incorporated, though clinical outcomes comprise only a minority of endpoints considered important by patients, particularly in specialized populations

Petrelintide's Amylin Analog MoA in the Weight Management Landscape

Several amylin receptor agonists are currently being developed alongside petrelintide for weight management and type 2 diabetes treatment. These second-generation amylin analogues leverage the same mechanism of central satiety induction and glucagon suppression, though specific intervention model details were not consistently reported across the literature.

Amylin's Resurgence: Petrelintide Targets Tolerability in Obesity

The decision by Zealand Pharma and Roche to push their once-weekly amylin analog, petrelintide, into Phase 3 trials for chronic weight management signals a potentially pivotal moment for the amylin class in obesity pharmacotherapy. For years, amylin's therapeutic promise, first realized with pramlintide, was constrained by its short half-life, necessitating multiple daily injections, and a notable incidence of gastrointestinal side effects, primarily nausea. While pramlintide effectively reduced HbA1c and body weight in diabetes, these practical limitations hindered its broader adoption, particularly for obesity without diabetes.

Petrelintide's emergence as a once-weekly formulation, coupled with reported double-digit weight loss and, crucially, 'placebo-like tolerability' in Phase 2, addresses these historical challenges head-on. This tolerability profile, if sustained in Phase 3, could be a game-changer, offering a significant advantage in a market where many highly effective weight-loss medications, including GLP-1 receptor agonists, are associated with dose-limiting GI adverse events. Such a profile could lead to higher patient adherence and a broader appeal, potentially expanding the overall population amenable to pharmacological weight management.

However, the path forward is not without its complexities. The primary risk lies in the need to rigorously replicate these promising Phase 2 results in larger, more diverse Phase 3 populations. Amylin analogs, including newer ones like cagrilintide, have shown varying degrees of nausea, and maintaining 'placebo-like tolerability' will be paramount. Furthermore, petrelintide will enter a fiercely competitive landscape, where dual and triple incretin agonists are already demonstrating impressive weight loss. Its long-term durability of effect and comprehensive safety data, particularly regarding cardiovascular outcomes, will be critical for establishing its place. If successful, petrelintide could not only reinvigorate the amylin class but also offer a compelling, well-tolerated option that complements or even competes with existing therapies, ultimately enriching the armamentarium against the global obesity pandemic.